Original articles
Cancan Zheng, Xiaomei Yu, Yiyao Liang, Yidong Zhu, Yan He, Long Liao, Dingkang Wang, Yanming Yang, Xingfeng Yin, Ang Li, Qingyu He, Bin Li. Targeting PFKL with penfluridol inhibits glycolysis and suppresses esophageal cancer tumorigenesis in an AMPK/FOXO3a/BIM-dependent manner[J]. Acta Pharmaceutica Sinica B, 2022, 12(3): 1271-1287

Targeting PFKL with penfluridol inhibits glycolysis and suppresses esophageal cancer tumorigenesis in an AMPK/FOXO3a/BIM-dependent manner
Cancan Zhenga, Xiaomei Yua, Yiyao Liangb, Yidong Zhuc, Yan Hec, Long Liaoa, Dingkang Wanga, Yanming Yanga, Xingfeng Yina, Ang Lib, Qingyu Hea, Bin Lia
a. MOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, Jinan University, Guangzhou 510632, China;
b. Guangdong Key Laboratory of Non-human Primate Research, Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Key Laboratory of CNS Regeneration, Ministry of Education, Jinan University, Guangzhou 510632, China;
c. MOE Key Laboratory of Tumor Molecular Biology and Guangdong Provincial Key Laboratory of Bioengineering Medicine, National Engineering Research Center of Genetic Medicine, Institute of Biomedicine, College of Life Science and Technology, Jinan University, Guangzhou 510632, China
Abstract:
As one of the hallmarks of cancer, metabolic reprogramming leads to cancer progression, and targeting glycolytic enzymes could be useful strategies for cancer therapy. By screening a small molecule library consisting of 1320 FDA-approved drugs, we found that penfluridol, an antipsychotic drug used to treat schizophrenia, could inhibit glycolysis and induce apoptosis in esophageal squamous cell carcinoma (ESCC). Gene profiling and Ingenuity Pathway Analysis suggested the important role of AMPK in action mechanism of penfluridol. By using drug affinity responsive target stability (DARTS) technology and proteomics, we identified phosphofructokinase, liver type (PFKL), a key enzyme in glycolysis, as a direct target of penfluridol. Penfluridol could not exhibit its anticancer property in PFKL-deficient cancer cells, illustrating that PFKL is essential for the bioactivity of penfluridol. High PFKL expression is correlated with advanced stages and poor survival of ESCC patients, and silencing of PFKL significantly suppressed tumor growth. Mechanistically, direct binding of penfluridol and PFKL inhibits glucose consumption, lactate and ATP production, leads to nuclear translocation of FOXO3a and subsequent transcriptional activation of BIM in an AMPK-dependent manner. Taken together, PFKL is a potential prognostic biomarker and therapeutic target in ESCC, and penfluridol may be a new therapeutic option for management of this lethal disease.
Key words:    Drug repurposing    Metabolic reprogramming    Glycolysis    PFKL    DARTS technology    Esophageal cancer    Penfluridol   
Received: 2021-06-09     Revised: 2021-08-18
DOI: 10.1016/j.apsb.2021.09.007
Funds: This work was supported by National Natural Science Foundation of China (31961160727, 81773085, and 81973339), National Key Research and Development Program of China (2017YFA0505100), and Guangdong Natural Science Research Grant International joint project (2021A0505030035, China).
Corresponding author: Qingyu He,E-mai:tqyhe@jnu.edu.cn;Bin Li,E-mai:libinjnu@163.com     Email:tqyhe@jnu.edu.cn;libinjnu@163.com
Author description:
Service
PDF(KB) Free
Print
0
Authors
Cancan Zheng
Xiaomei Yu
Yiyao Liang
Yidong Zhu
Yan He
Long Liao
Dingkang Wang
Yanming Yang
Xingfeng Yin
Ang Li
Qingyu He
Bin Li

References:
[1] Morandi A, Indraccolo S. Linking metabolic reprogramming to therapy resistance in cancer. Biochim Biophys Acta Rev Cancer 2017; 1868: 1-6
[2] Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011; 11: 325-337
[3] Feng Y, Zhang Y, Cai Y, Liu R, Lu M, Li T, et al. A20 targets PFKL and glycolysis to inhibit the progression of hepatocellular carcinoma. Cell Death Dis 2020; 11: 89
[4] Zhao Y, Hu X, Liu Y, Dong S, Wen Z, He W, et al. ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway. Mol Cancer 2017; 16: 79
[5] Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008; 30: 214-226
[6] An Y, Wang B, Wang X, Dong G, Jia J, Yang Q. SIRT1 inhibits chemoresistance and cancer stemness of gastric cancer by initiating an AMPK/FOXO3 positive feedback loop. Cell Death Dis 2020; 11: 115
[7] Liu Z, Shi Z, Lin J, Zhao S, Hao M, Xu J, et al. Piperlongumine-induced nuclear translocation of the FOXO3A transcription factor triggers BIM-mediated apoptosis in cancer cells. Biochem Pharmacol 2019; 163: 101-110
[8] Lomenick B, Hao R, Jonai N, Chin RM, Aghajan M, Warburton S, et al. Target identification using drug affinity responsive target stability (DARTS). Proc Natl Acad Sci U S A 2009; 106: 21984-21989
[9] Pai MY, Lomenick B, Hwang H, Schiestl R, McBride W, Loo JA, et al. Drug affinity responsive target stability (DARTS) for small-molecule target identification. Methods Mol Biol 2015; 1263: 287-298
[10] Li L, Li L, Li W, Chen T, Bin Z, Zhao L, et al. TAp73-induced phosphofructokinase-1 transcription promotes the Warburg effect and enhances cell proliferation. Nat Commun 2018; 9: 4683
[11] Yalcin A, Telang S, Clem B, Chesney J. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Exp Mol Pathol 2009; 86: 174-179
[12] Nakajima H. Phosphofructokinase (PFK). Nihon Rinsho 1995; 53: 1241-1246
[13] Yang J, Li J, Le Y, Zhou C, Zhang S, Gong Z. PFKL/miR-128 axis regulates glycolysis by inhibiting AKT phosphorylation and predicts poor survival in lung cancer. Am J Cancer Res 2016; 6: 473-485
[14] Zheng J, Luo J, Zeng H, Guo L, Shao G. 125I suppressed the Warburg effect viaregulating miR-338/PFKL axis in hepatocellular carcinoma. Biomed Pharmacother 2019; 119: 109402
[15] Xu WW, Zheng CC, Zuo Q, Li JQ, Hong P, Qin YR, et al. Genome-wide identification of key regulatory lncRNAs in esophageal cancer metastasis. Signal Transduct Target Ther 2021; 6: 88
[16] Xu WW, Huang ZH, Liao L, Zhang QH, Li JQ, Zheng CC, et al. Direct targeting of CREB1 with imperatorin inhibits TGFβ2-ERK signaling to suppress esophageal cancer metastasis. Adv Sci (Weinh) 2020; 7: 2000925
[17] Hu HF, Xu WW, Li YJ, He Y, Zhang WX, Liao L, et al. Anti-allergic drug azelastine suppresses colon tumorigenesis by directly targeting ARF1 to inhibit IQGAP1-ERK-Drp1-mediated mitochondrial fission. Theranostics 2021; 11: 1828-1844
[18] Huang XH, Yan X, Zhang QH, Hong P, Zhang WX, Liu YP, et al. Direct targeting of HSP90 with daurisoline destabilizes beta-catenin to suppress lung cancer tumorigenesis. Cancer Lett 2020; 489: 66-78
[19] Hu HF, Xu WW, Zhang WX, Yan X, Li YJ, Li B, et al. Identification of miR-515-3p and its targets, vimentin and MMP3, as a key regulatory mechanism in esophageal cancer metastasis: functional and clinical significance. Signal Transduct Target Ther 2020; 5: 271
[20] Xu WW, Li B, Guan XY, Chung SK, Wang Y, Yip YL, et al. Cancer cell-secreted IGF2 instigates fibroblasts and bone marrow-derived vascular progenitor cells to promote cancer progression. Nat Commun 2017; 8: 14399
[21] Hong P, Liu QW, Xie Y, Zhang QH, Liao L, He QY, et al. Echinatin suppresses esophageal cancer tumor growth and invasion through inducing AKT/mTOR-dependent autophagy and apoptosis. Cell Death Dis 2020; 11: 524
[22] Li B, Xu WW, Guan XY, Qin YR, Law S, Lee NP, et al. Competitive binding between Id1 and E2F1 to Cdc20 regulates E2F1 degradation and thymidylate synthase expression to promote esophageal cancer chemoresistance. Clin Cancer Res 2016; 22: 1243-1255
[23] Chicca A, Schafroth MA, Reynoso-Moreno I, Erni R, Petrucci V, Carreira EM, et al. Uncovering the psychoactivity of a cannabinoid from liverworts associated with a legal high. Sci Adv 2018; 4: eaat2166
[24] Abdel-Salam OM, El-Sayed El-Shamarka M, Salem NA, El-Din MGA. Effects of Cannabis sativa extract on haloperidol-induced catalepsy and oxidative stress in the mice. EXCLI J 2012; 11: 45-58
[25] Naskar A, Manivasagam T, Chakraborty J, Singh R, Thomas B, Dhanasekaran M, et al. Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism. J Pineal Res 2013; 55: 304-312
[26] Naskar A, Prabhakar V, Singh R, Dutta D, Mohanakumar KP. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. J Pineal Res 2015; 58: 262-274
[27] Wang P, Liang Y, Chen K, Yau SY, Sun X, Cheng KK, et al. Potential involvement of adiponectin signaling in regulating physical exercise-elicited hippocampal neurogenesis and dendritic morphology in stressed mice. Front Cell Neurosci 2020; 14: 189
[28] Greenbaum L, Lifschytz T, Zozulinsky P, Broner EC, Slonimsky A, Kohn Y, et al. Alteration in RGS2 expression level is associated with changes in haloperidol induced extrapyramidal features in a mutant mouse model. Eur Neuropsychopharmacol 2012; 22: 379-386
[29] Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033
[30] Lin SC, Hardie DG. AMPK: sensing glucose as well as cellular energy status. Cell metabolism 2018; 27: 299-313
[31] Li D, Luo L, Xu M, Wu J, Chen L, Li J, et al. AMPK activates FOXO3a and promotes neuronal apoptosis in the developing rat brain during the early phase after hypoxia-ischemia. Brain Res Bull 2017; 132: 1-9
[32] Chiacchiera F, Simone C. The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle 2010; 9: 1091-1096
[33] Li C, Xiao XQ, Qian YH, Zhou ZY. The CtBP1-p300-FOXO3a transcriptional complex represses the expression of the apoptotic regulators Bax and BIM in human osteosarcoma cells. J Cell Physiol 2019; 234: 22365-22377
[34] Sun T, Zhang J, Deng B, Fan X, Long T, Jin H, et al. FOXO1 and FOXO3a sensitize non-small-cell lung cancer cells to cisplatin-induced apoptosis independent of BIM. Acta Biochim Biophys Sin (Shanghai) 2020; 52: 1348-1359
[35] Sun Q, Li S, Wang Y, Peng H, Zhang X, Zheng Y, et al. Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis. Cell Death Differ 2018; 25: 1160-1173
[36] Chang YC, Yang YC, Tien CP, Yang CJ, Hsiao M. Roles of aldolase family genes in human cancers and diseases. Trends Endocrinol Metab 2018; 29: 549-559
[37] He Y, Luo Y, Zhang D, Wang X, Zhang P, Li H, et al. PGK1-mediated cancer progression and drug resistance. Am J Cancer Res 2019; 9: 2280-2302
[38] Vincent EE, Sergushichev A, Griss T, Gingras MC, Samborska B, Ntimbane T, et al. Mitochondrial phosphoenolpyruvate carboxykinase regulates metabolic adaptation and enables glucose-independent tumor growth. Mol Cell 2015; 60: 195-207
[39] Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017; 45: W98-W102
[40] Li J, Zhong L, Wang F, Zhu H. Dissecting the role of AMP-activated protein kinase in human diseases. Acta Pharm Sin B 2017; 7: 249-259
[41] Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol 2018; 19: 121-135
[42] Liu Y, Ao X, Ding W, Ponnusamy M, Wu W, Hao X, et al. Critical role of FOXO3a in carcinogenesis. Mol Cancer 2018; 17: 104
[43] Cao MQ, You AB, Zhu XD, Zhang W, Zhang YY, Zhang SZ, et al. miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. J Hematol Oncol 2018; 11: 12
[44] Farhan M, Wang H, Gaur U, Little PJ, Xu J, Zheng W. FOXO signaling pathways as therapeutic targets in cancer. Int J Biol Sci 2017; 13: 815-827
[45] Czabotar PE, Colman PM, Huang DC. Bax activation by BIM?. Cell Death Differ 2009; 16: 1187-1191
[46] Akiyama T, Dass CR, Choong PF. BIM-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther 2009; 8: 3173-3180
[47] Zancan P, Sola-Penna M, Furtado CM, Da Silva D. Differential expression of phosphofructokinase-1 isoforms correlates with the glycolytic efficiency of breast cancer cells. Mol Genet Metab 2010; 100: 372-378
[48] Zhang X, Wang J, Zhuang J, Liu C, Gao C, Li H, et al. A novel glycolysis-related four-mRNA signature for predicting the survival of patients with breast cancer. Front Genet 2021; 12: 606937
[49] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424
[50] Lu Z, Ren Y, Yang L, Jia A, Hu Y, Zhao Y, et al. Inhibiting autophagy enhances sulforaphane-induced apoptosis via targeting NRF2 in esophageal squamous cell carcinoma. Acta Pharm Sin B 2021; 11: 1246-1260
[51] Codipilly DC, Qin Y, Dawsey SM, Kisiel J, Topazian M, Ahlquist D, et al. Screening for esophageal squamous cell carcinoma: recent advances. Gastrointest Endosc 2018; 88: 413-426
[52] Moffat JG, Rudolph J, Bailey D. Phenotypic screening in cancer drug discovery-past, present and future. Nat Rev Drug Discov 2014; 13: 588-602
[53] Jiang YY, Lin DC, Mayakonda A, Hazawa M, Ding LW, Chien WW, et al. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma. Gut 2017; 66: 1358-1368
[54] Ranjan A, Gupta P, Srivastava SK. Penfluridol: an antipsychotic agent suppresses metastatic tumor growth in triple-negative breast cancer by inhibiting integrin signaling axis. Cancer Res 2016; 76: 877-890
Similar articles: